NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE: KMDA) today announced that Israeli Ministry of Health (IMOH) has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility in Beit Kama, Israel. The audit was performed as part of the Ministry of Health's routine evaluation of the company's manufacturing process for its plasma-derived protein therapeutics. The audit concludes that Kamada complies with the GMP requirements of the IMOH. As the IMOH is also a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), this audit is also issued under the provisions of the Conformity...
↧